This page contains brief information about daratumumab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Daratumumab is approved to be used alone or with other drugs to treat:
- Multiple myeloma.
- It is used with dexamethasone and either bortezomib or lenalidomide in patients who have already received at least one other type of treatment.
- It is used alone in patients who have already received at least three other types of treatment, including a proteasome inhibitor and an immunomodulating agent.
Daratumumab is also being studied in the treatment of other types of cancer.
More About Daratumumab
Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.
MedlinePlus Information on Daratumumab – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Daratumumab – Check for trials from TCH’s list of cancer clinical trials now accepting patients.